SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Bitter-Suermann D. The anaphylatoxins. In: RotherK, TillGO, editors. The complement system. Berlin: Springer-Verlag; 1988. p. 367384.
  • 2
    Yancey KB. Biological properties of human C5a: selected in vitro and in vivo studies. Clin Exp Immunol 1988; 71: 207210.
  • 3
    Haynes DR, Harkin DG, Bignold LP, Hutchens MJ, Taylor SM, Fairlie DP. Inhibition of C5a-induced neutrophil chemotaxis and macrophage cytokine production in vitro by a new C5a receptor antagonist. Biochem Pharmacol 2000; 60: 729733.
  • 4
    Jose PJ, Moss IK, Maini RN, Williams TJ. Measurement of the chemotactic complement fragment C5a in rheumatoid synovial fluids by radioimmunoassay: role of C5a in the acute inflammatory phase. Ann Rheum Dis 1990; 49: 747752.
  • 5
    Hogasen K, Mollnes TE, Harboe M, Gotze O, Hammer HB, Oppermann M. Terminal complement pathway activation and low lysis inhibitors in rheumatoid arthritis synovial fluid. J Rheumatol 1995; 22: 2428.
  • 6
    Kiener HP, Baghestanian M, Dominkus M, Walchshofer S, Ghannadan M, Willheim M, et al. Expression of the C5a receptor (CD88) on synovial mast cells in patients with rheumatoid arthritis. Arthritis Rheum 1998; 41: 233245.
  • 7
    Brodeur JP, Ruddy S, Schwartz LB, Moxley G. Synovial fluid levels of complement SC5b-9 and fragment Bb are elevated in patients with rheumatoid arthritis. Arthritis Rheum 1991; 34: 15311537.
  • 8
    Makinde VA, Senaldi G, Jawad AS, Berry H, Vergani D. Reflection of disease activity in rheumatoid arthritis by indices of activation of the classical complement pathway. Ann Rheum Dis 1989; 48: 302306.
  • 9
    Morgan BP, Daniels RH, Williams BD. Measurement of terminal complement complexes in rheumatoid arthritis. Clin Exp Immunol 1988; 73: 473478.
  • 10
    Kemp PA, Spragg JH, Brown JC, Morgan BP, Gunn CA, Taylor PW. Immunohistochemical determination of complement activation in joint tissues of patients with rheumatoid arthritis and osteoarthritis using neoantigen-specific monoclonal antibodies. J Clin Lab Immunol 1992; 37: 147162.
  • 11
    Kourounakis L, Nelson RA Jr, Kupusta MA. The effect of a cobra venom factor on complement and adjuvant-induced disease in rats. Arthritis Rheum 1973; 16: 7176.
  • 12
    Goodfellow RM, Williams AS, Levin JL, Williams BD, Morgan BP. Local therapy with soluble complement receptor 1 (sCR1) suppresses inflammation in rat monoarticular arthritis. Clin Exp Immunol 1997; 110: 4552.
  • 13
    Goodfellow RM, Williams AS, Levin JL, Williams BD, Morgan BP. Soluble complement receptor one (sCR1) inhibits the development and progression of rat collagen-induced arthritis. Clin Exp Immunol 2000; 119: 210216.
  • 14
    Mizuno M, Nishikawa K, Morgan BP, Matsuo S. Comparison of the suppressive effects of soluble CR1 and C5a receptor antagonist in acute arthritis induced in rats by blocking of CD59. Clin Exp Immunol 2000; 119: 368375.
  • 15
    Wang Y, Rollins SA, Madri JA, Matis LA. Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease. Proc Natl Acad Sci U S A 1995; 92: 89558959.
  • 16
    Mizuno M, Nishikawa K, Okada N, Matsuo S, Ito K, Okada H. Inhibition of a membrane complement regulatory protein by a monoclonal antibody induces acute lethal shock in rats primed with lipopolysaccharide. J Immunol 1999; 162: 54775482.
  • 17
    Moreland LW, Russell AS, Paulus HE. Management of rheumatoid arthritis: the historical context. J Rheumatol 2001; 28: 14311452.
  • 18
    Van den Berg WB. Impact of NSAID and steroids on cartilage destruction in murine antigen induced arthritis. J Rheumatol Suppl 1991; 27: 122123.
  • 19
    Wong AK, Finch AM, Pierens GK, Craik DJ, Taylor SM, Fairlie DP. Small molecular probes for G-protein-coupled C5a receptors: conformationally constrained antagonists derived from the C terminus of the human plasma protein C5a. J Med Chem 1998; 41: 34173425.
  • 20
    Finch AM, Wong AK, Paczkowski NJ, Wadi SK, Craik DJ, Fairlie DP, et al. Low-molecular-weight peptidic and cyclic antagonists of the receptor for the complement factor C5a. J Med Chem 1999; 42: 19651974.
  • 21
    Strachan AJ, Woodruff TM, Haaima G, Fairlie DP, Taylor SM. A new small molecule C5a receptor antagonist inhibits the reverse-passive Arthus reaction and endotoxic shock in rats. J Immunol 2000; 164: 65606565.
  • 22
    Strachan AJ, Shiels IA, Reid RC, Fairlie DP, Taylor SM. Inhibition of immune-complex mediated dermal inflammation in rats following either oral or topical administration of a small molecule C5a receptor antagonist. Br J Pharmacol 2001; 134: 17781186.
  • 23
    Arumugam TV, Shiels IA, Woodruff TM, Reid RC, Fairlie DP, Taylor SM. Protective effect of a new C5a receptor antagonist against ischemia-reperfusion injury in the rat small intestine. J Surg Res 2002; 103: 260267.
  • 24
    Woodruff TM, Strachan AJ, Sanderson SD, Monk PN, Wong AK, Fairlie DP, et al. Species dependence for binding of small molecule agonist and antagonists to the C5a receptor on polymorphonuclear leukocytes. Inflammation 2001; 25: 171177.
  • 25
    Paczkowski NJ, Finch AM, Whitmore JB, Short AJ, Wong AK, Monk PN, et al. Pharmacological characterization of antagonists of the C5a receptor. Br J Pharmacol 1999; 128: 14611466.
  • 26
    Kitsis E, Weissmann G. The role of the neutrophil in rheumatoid arthritis. Clin Orthop 1991; 6372.
  • 27
    Katona IM, Ohura K, Allen JB, Wahl LM, Chenoweth DE, Wahl SM. Modulation of monocyte chemotactic function in inflammatory lesions: role of inflammatory mediators. J Immunol 1991; 146: 708714.
  • 28
    Rioux P. TP-10 (AVANT immunotherapeutics). Curr Opin Investig Drugs 2001; 2: 364371.
  • 29
    Weissmann G, Korchak H. Rheumatoid arthritis: the role of neutrophil activation. Inflammation 1984; 8 Suppl: S314.
  • 30
    Kowanko IC, Ferrante A. Interferon-γ increases human neutrophil-mediated cartilage proteoglycan degradation. Clin Exp Rheumatol 1992; 10: 123129.
  • 31
    Kinne RW, Brauer R, Stuhlmuller B, Palombo-Kinne E, Burmester GR. Macrophages in rheumatoid arthritis. Arthritis Res 2000; 2: 189202.
  • 32
    Manicourt DH, Poilvache P, van Egeren A, Devogelaer JP, Lenz ME, Thonar EJ. Synovial fluid levels of tumor necrosis factor α and oncostatin M correlate with levels of markers of the degradation of crosslinked collagen and cartilage aggrecan in rheumatoid arthritis but not in osteoarthritis. Arthritis Rheum 2000; 43: 281288.
  • 33
    Short A, Wong AK, Finch AM, Haaima G, Shiels IA, Fairlie DP, et al. Effects of a new C5a receptor antagonist on C5a- and endotoxin-induced neutropenia in the rat. Br J Pharmacol 1999; 126: 551554.
  • 34
    Langenegger T, Michel BA. Drug treatment for rheumatoid arthritis. Clin Orthop 1999; 2230.
  • 35
    Lundberg C, Marceau F, Hugli TE. C5a-induced hemodynamic and hematologic changes in the rabbit: role of cyclooxygenase products and polymorphonuclear leukocytes. Am J Pathol 1987; 128: 471483.
  • 36
    Regal JF, Fraser DG. Recombinant human C5a-induced bronchoconstriction in the guinea-pig: a histamine independent mechanism. Pulm Pharmacol 1990; 3: 7987.
  • 37
    Ito BR, Roth DM, Engler RL. Thromboxane A2 and peptidoleukotrienes contribute to the myocardial ischemia and contractile dysfunction in response to intracoronary infusion of complement C5a in pigs. Circ Res 1990; 66: 596607.
  • 38
    Camussi G, Lupia E. The future role of anti-tumour necrosis factor (TNF) products in the treatment of rheumatoid arthritis. Drugs 1998; 55: 613620.
  • 39
    Alldred A. Etanercept in rheumatoid arthritis. Expert Opin Pharmacother 2001; 2: 11371148.
  • 40
    Hopken U, Mohr M, Struber A, Montz H, Burchardi H, Gotze O, et al. Inhibition of interleukin-6 synthesis in an animal model of septic shock by anti-C5a monoclonal antibodies. Eur J Immunol 1996; 26: 11031109.
  • 41
    Mulligan MS, Schmid E, Beck-Schimmer B, Till GO, Friedl HP, Brauer RB, et al. Requirement and role of C5a in acute lung inflammatory injury in rats. J Clin Invest 1996; 98: 503512.